Page 2 - Advanced Ovarian News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AstraZeneca: IMFINZI (durvalumab) plus LYNPARZA (olaparib) reduced the risk of disease progression or death by 45% vs chemotherapy in advanced or recurrent endometrial cancer

AstraZeneca: IMFINZI (durvalumab) plus LYNPARZA (olaparib) reduced the risk of disease progression or death by 45% vs chemotherapy in advanced or recurrent endometrial cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomImfinzimonotherapy imfinziarmIndiens wirtschaftSusan galbraithChelsea fordShannonn westinIhre chancenBrendan mcevoyEuropean society for medical oncologyCanadian agency for drugsMerck co incWorld cancer research fund internationalTechnologies in healthUniversity of texas md anderson cancer centerUs electronic health records

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs chemotherapy in advanced or recurrent endometrial cancer

WILMINGTON, Del. (BUSINESS WIRE) Oct 21, 2023

United statesUnited kingdomChelsea fordBrendan mcevoySusan galbraithShannonn westinEuropean society for medical oncologyMerck co incCanadian agency for drugsTechnologies in healthUniversity of texas md anderson cancer centerWorld cancer research fund internationalUs electronic health recordsAmerican cancer societyMedical oncologyControl arm

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAmir jazaeriWilliamh goodwin jrTyler jacksKim sutton golodetzWilliam hunter goodwinCorinne le goffDavidh kochMemorial sloan kettering cancer centerMassachusetts institute of technologyImunon incJeffreyw churchExchange commissionKoch institute for integrative cancer researchUniversity of texas md anderson cancer centerDana farber cancer institute

Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesJulie schneidermanIra winerChristian marsolaisPhilippe dubucSudocetaxel zendusortideKarmanos cancer centerDrug administrationTheratechnologies incAmerican society of clinical oncologyMilestone for companyCommunications corporate affairsAnnounces dosingFirst patientUpdated clinical trialAdvanced ovarian

AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO

AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomSusan galbraithImfinziand lynparzaasChelsea fordDave fredricksonBrendan mcevoyDaiichi sankyoDaiichi sankyo incDaiichi sankyo companyMerck co incEuropean society for medical oncologyPresidential symposiaEuropean societyMedical oncologyPresidential symposiumExecutive vice president